Improving outcomes in patients with musculoskeletal pain Musculoskeletal Diseases
Conditions
Interventions
The intervention of the trial is the implementation of a new tool, risk of pain spreading (ROPS), including individualized care pathways based on the ROPS. Patients in the intervention group are divid
Sponsors
University of Oulu
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patients who will be visiting physiotherapists in primary healthcare due to MSK pain. MSK pain is referred to pain in the following anatomical areas: neck/shoulder, upper limb, lower limb, and/or back, or multisite pain (pain in many of these locations). 2. At least 18 years of age 3. Possibility and ability to use a smart device (phone, computer, or tablet) 4. Consent to take part in the trial.
Exclusion criteria
Exclusion criteria: 1. Red-flag symptoms/findings (acute urinary retention, faecal incontinence, perianal anesthesia, symptoms of paralysis or major numbness of the limbs, fever or unexplainable weight loss related to pain) 2. Trauma as a reason for pain in the past six months 3. Memory disorder 4. Cancer 5. Serious mental health disorder, such as schizophrenia or psychotic depression 6. Pregnancy 7. Operation on the area where musculoskeletal pain occurs within the past year 8. Insufficient Finnish language skills for participating in the interviews and answering the surveys
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary implementation/sustainability outcomes 1.The usage of the ROPS (Risk of Pain Spreading questionnaire) is measured continuously during the intervention phase with checklists targeted at physiotherapists participating in the trial 2.The design of care pathway according to the ROPS (has it occurred or not, and if it has, how) is measured continuously during the intervention phase with checklists targeted at physiotherapists participating in the trial Primary patient-level outcome measure 1.Functional ability is primarily defined with the PROMIS-29+2 Profile and is measured between the baseline and the follow-up periods of 6, 12 and 36 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary implementation outcomes 1. Feasibility of the intervention is measured using face-to-face or video call semi-structured interviews and DIBQ-mp questionnaire (modified version of the Determinants of Implementation Behavior Questionnaire), targeted at physiotherapists and patients, at 1 and 12 months after the intervention 2. Adherence to the intervention is measured with questionnaires targeted at patients at 6, 12, and 36 months after the intervention Secondary patient-level outcome measures 1. Use of health services (visits to different professionals during the follow-up period, care periods, number of and reasons for visits) is based on national registers and questionnaires and is measured at baseline and 6, 12, and 36 months 2. Sick leaves are based on national registers and questionnaires and are measured at baseline and 6, 12, and 36 months 3. Disability pensions are based on national registers and questionnaires and are measured at baseline and 6, 12, and 36 months 4. Health-related quality of life is measured using EuroQol five-dimension, five-level version, EQ-5D-5L, at baseline, and 6, 12, and 36 months 5. Intensity of pain is measured using Numerical Rating Scale (0-10) at baseline and 6, 12, and 36 months 6. Bothersomeness of pain is measured using Numerical Rating Scale (0-10) at baseline and 6, 12, and 36 months 7. Number of pain sites is measured using self-reported pain sites at baseline and 6, 12, and 36 months 8. Patient’s sense of enablement is measured using a modified version of the patient’s sense of coping (Patient Enablement Instrument, PEI) at 6, 12, and 36 months 9. ROPS value is measured using ROPS questionnaire at baseline and 6, 12, and 36 months. 10. Patient’ impression of change is measured using Patient’s Global Impression of Change questionnaire at 6, 12, and 36 months 11. Patients’ experiences are measured using Face-to-face or video call interviews at 1 and 12 months after the intervention | — |
Countries
Finland
Contacts
Public ContactJaro;Eveliina Karppinen;Heikkala
;
Outcome results
None listed